Pasithea TherapeuticsKTTA
13F holders, Q1 2024 (March 31)6holders
$7.26avg. 13F price*
At the end of Q1 2024, 6 institutions reported holding Pasithea Therapeutics Corp. (KTTA) in their 13F filings. The largest holders were ADAR1 Capital Management, LLC ($201K), Tower Research Capital LLC (TRC) ($10K) and UBS Group AG ($4K).
- Company
- Pasithea Therapeutics Corp.
- CUSIP
- 70261F202
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 7 | $218K |
| Exits | 0 | $0 |
Ownership 6 holders
| ADAR1 Capital Management, LLC | 0.05% | New | 27,696 | $201K |
| Tower Research Capital LLC (TRC) | 0.00% | New | 1,345 | $10K |
| UBS Group AG | 0.00% | New | 608 | $4K |
| Royal Bank of Canada | 0.00% | New | 250 | $2K |
| JPMorgan Chase & Co. | 0.00% | New | 150 | $1K |
| Wells Fargo & Company | 0.00% | New | 6 | $44 |
"% of holder's portfolio" is KTTA's weight in each manager's 13F, not the share of Pasithea Therapeutics Corp. the manager owns.